StemCell Therapy

Biotechnology is a technological application that uses living organisms, biological systems or derivatives to produce or modify products or processes for specific use. Biotechnology encompasses a wide range of procedures required for modifying living organisms to fulfill various demands for domestic as well as industrial applications. Thus, biotechnology is a general term that is used for a wide range of techniques that are involved in the production, transformation or degradation of the desired product. Biotechnology based chemicals are the products that are manufactured by applying various techniques such as fermentation. Biotechnology based chemicals comprises polyhydroxyalkanoates, lactic acid, lysine, citric acid, glutamic acid and threonine. The technology used in manufacturing biotechnology based chemicals are simple however, the entire production process should be carried out under the supervision of trained personnel. Glutamic acid is the most widely used amino acid manufactured as well as consumed in the world. Biotechnology based chemicals find application in pharmaceuticals, food industry, animal feed and consumer goods manufacturing industries among others.

Pharmaceutical industry is the largest consumer of biotechnology based chemicals. The growing demand for natural medicines than that compared to synthetic chemicals is expected to augment the overall demand for biotechnology based chemicals. In addition, growing awareness of the several side effects associated with the chemical drugs is expected to boost the overall biotechnology based chemicals market. The animal feed industry is also one of the major consumers of biotechnology based chemicals market. The growing demand for lysine in animal feed is expected to boost the overall demand for biotechnology chemicals market. Lactic acid finds applications in a wide range of industries. The growing demand for manufacturing polylactic acid (PLA) plastics boost the demand for lactic acid which in turn is expected to augment the overall biotechnology based chemicals market. However, high cost associated with the manufacturing of biotechnology based chemicals is expected to restrain the overall growth of the market.

The growing demand for pharmaceutical products has expected to augment the overall demand for biotechnology based chemicals in China. China is the largest consumer of biotechnology based chemicals market. The growing demand for citric acid especially from the food and beverage industry in China is expected to augment the overall demand for biotechnology based chemicals market. North America is expected to be the next largest consumer of biotechnology based chemicals owing to the growing consumer preference for natural products. The demand for biotechnology based chemicals is expected to grow rapidly owing to the presence of dominant animal feed and other end use industries in Europe.

Lysine is a crucial ingredient used in the animal feed for swine and poultry feeds. Thus, the growing demand for animal feed is expected to boost the overall demand for biotechnology based chemicals market. Rest of Asia Pacific is expected to experience rapid growth in the demand for biotechnology based chemicals owing to the growing pharmaceutical industry in the region. However, Rest of the World is expected to exhibit sluggish growth in the demand for biotechnology based chemicals in the next few years.

Kemin, BioAmber Inc. and Stora Enso are some of the major participants in the biotechnology based chemicals market. The companys present in the focus mainly towards research as they intend to introduce innovative products in the market.

This post was originally published on Market Research Sheets

Go here to see the original:
Biotechnology Based Chemicals Market Key Players, Industry Overview and Forecast Analysis by 2020 - Market Research Sheets

NEW YORK, Dec. 23, 2019 /PRNewswire/ --

The global liquid handling technology market is expected to reach US$ 5,705.63 Mn in 2027 from US$ 3,201.36 Mn in 2018. The market is estimated to grow with a CAGR of 6.7% from 2019-2027.

Read the full report: https://www.reportlinker.com/p05833605/?utm_source=PRN

The key factors that are driving the growth of liquid handling technology market are increasing drug discovery activities, growing biopharmaceutical industry and rising research and development expenses. Whereas, the market is expected to have slow growth due to the scarcity of skilled professionals during the forecast period.In the past few years, the biopharmaceutical industry has experienced exponential growth and is growing in the developing region at an extraordinary pace.The North American region owe highly advanced techniques that enable it to offers more of the biotechnology products in the market.

Regions such as Europe and the Asia Pacific have speeded up their investments and interest in the field of biotechnology, whereas regions such as South and Central America and the Middle East are developing their biotechnology industry significantly.Developed regions are consolidated with various market leaders and are experiencing a rising number of start-up biotechnology companies.The developing regions are collaborating with various market leaders and government entities to expand research and development activities in the biotechnology sector.

For instance, North American and European biotechnology sectors are heading towards the Asia Pacific region due to increased clinical activities. Since 2016, in the Asia Pacific, there are has been an increase in clinical activities from the biotech companies approximately by 26%.The biotechnology industry is also experiencing rising initiatives by the government and private bodies. For instance, in September 2017, the U.S.-Ukraine Foundation has launched a new biotechnology initiative to support the developments in the field of biotechnology, which resulted in the exertion to build new networking opportunities. Also, the U.S.-Ukraine Foundation has become a member of the Biotechnology Innovation Organization (BIO) and is the global leader of the trade association representing biotechnology companies, state biotechnology centers, academic institutions, and related organizations across the United States and more than 30 other nations.Thus, owing to the rise in biotechnology sector, increasing initiatives and growing clinical activities in the biotechnology industry are likely to increase the growth of the liquid handling technology market during the forecast period.The liquid handling technology market is segmented on the basis of product, type, application and end user.The market based on product segment is classified as automated workstations, small devices, consumables.

On the basis of type the market is classified as automated liquid handling, manual liquid handling, and semi-automated liquid handling. Based on the application segment market is divided into drug discovery & ADME-Tox Research, cancer and genomic research, bioprocessing/biotechnology. Based on end user the market is categorized as pharmaceutical and biotechnology companies, contract research organization, academic and research institutes

Read the full report: https://www.reportlinker.com/p05833605/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/the-global-liquid-handling-technology-market-is-expected-to-reach-us-5-705-63-mn-in-2027-from-us-3-201-36-mn-in-2018--300979003.html

SOURCE Reportlinker

Visit link:
The global liquid handling technology market is expected to reach US$ 5705.63 Mn in 2027 from US$ 3201.36 Mn in 2018 - P&T Community

Puma Biotechnology, Inc. [PBYI] took an upward turn with a change of -1.36%, trading at the price of $8.73 during the trading session on . The price movement in correlation with percentage of the mentioned increase can allow a valuable insight to investors. During the last trading session 528911 shares changed hands being bought and sold, while Puma Biotechnology, Inc. shares have an average trading volume of 1.76M shares for that time period. PBYI monthly volatility recorded 10.00%, in the meanwhile having share price volatility for the week set at 8.87%. PS value for PBYI stocks is 1.29 with PB recorded at 20.11.

Its stock price has been found in the range of 6.26 to 43.90. This is compared to its latest closing price of $8.85.

Keep on the lookout for this organizations next scheduled financial results, which are expected to be made public on Thu 27 Feb (In 62 Days).

Now lets turn to look at profitability: with a current Operating Margin for Puma Biotechnology, Inc. [PBYI] sitting at -37.72 and its Gross Margin at +86.21, this companys Net Margin is now -33.90%. These metrics indicate that this company is not generating as much profit, after accounting for expenses, compared to its market peers.

This companys Return on Total Capital is -65.75, and its Return on Invested Capital has reached -55.70%. Its Return on Equity is -259.28, and its Return on Assets is -53.49. These metrics suggest that this Puma Biotechnology, Inc. does a poor job of managing its assets, and likely wont be able to provide successful business outcomes for its investors in the near term.

Turning to investigate this organizations capital structure, Puma Biotechnology, Inc. [PBYI] has generated a Total Debt to Total Equity ratio of 442.74. Similarly, its Total Debt to Total

What about valuation? This companys Enterprise Value to EBITDA is -3.71. The Enterprise Value to Sales for this firm is now 1.15, and its Total Debt to Enterprise Value stands at 0.20. Puma Biotechnology, Inc. [PBYI] has a Price to Book Ratio of 22.73.

Shifting the focus to workforce efficiency, Puma Biotechnology, Inc. [PBYI] earns $922,761 for each employee under its payroll. Similarly, this companys Receivables Turnover is 15.88 and its Total Asset Turnover is 1.18. This publicly-traded organizations liquidity data is also interesting: its Quick Ratio is 2.99 and its Current Ratio is 3.02. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.

Puma Biotechnology, Inc. [PBYI] has 40.85M shares outstanding, amounting to a total market cap of $361.52M. Its stock price has been found in the range of 6.26 to 43.90. At its current price, it has moved down by -80.11% from its 52-week high, and it has moved up 39.46% from its 52-week low.

This stocks Beta value is currently 1.64, which indicates that it is 8.87% more volatile that the wider market. This stocks Relative Strength Index (RSI) is at 50.71. This RSI score is good, suggesting this stock is neither overbought or oversold.

Shares of Puma Biotechnology, Inc. [PBYI], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this companys financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.

See the article here:
Puma Biotechnology, Inc. [PBYI] could give the highest percentage gains? Check Out this Analysis - The Dwinnex

As they finalize rules to control the cost of prescription drugs, state officials are meeting new resistance from the pharmaceutical industry.

Legislators and Governor Charlie Baker approved a change in law this summer that allows the administration to curb drug costs in the state Medicaid program, or MassHealth, by negotiating discounts directly with drug companies. If negotiations are unsuccessful, the administration can establish a target value for certain high-cost drugs, hold a public hearing, and refer the matter to the Health Policy Commission, a watchdog agency, for further review.

Then, the commission can demand more information from drug makers, but that information would remain out of public view.

Administration officials and the Health Policy Commission have been drafting detailed regulations to implement the law. But the Massachusetts Biotechnology Council, which represents biopharmaceutical companies, said the proposed regulations go too far.

We have strong concerns, said Zachary Stanley, a spokesman for MassBio. We think they are going beyond what the enabling law allows them to.

Stanley said drug makers are particularly worried that the administration wants to publicly post the target value of drugs. And theyre troubled by the amount and type of information that the Health Policy Commission plans to require from companies that are undergoing a review. For example, companies dont want to disclose the net prices that various insurance companies pay for their drugs or share their research and development costs.

The Pharmaceutical Research and Manufacturers of America, or PhRMA, raised similar issues, telling state officials it is deeply concerned about several aspects of the proposed regulations.

Baker first proposed a plan to tackle drug costs in MassHealth in January and drew immediate fire from pharmaceutical lobbyists. The proposal made for a lengthy debate at the State House. In late July, state lawmakers finally approved a version of Bakers plan but softened some of the language. At the time, MassBio called it a good compromise.

At this point, we want to make sure the law is enacted faithfully to what the Legislature intended, Stanley said.

Drug company lobbyists have argued that controls on prices could stifle innovation, particularly in the biotech hub of Massachusetts, where research labs represent an important piece of the economy.

But as drug costs continue rising for patients and for state governments policy makers have continued to target pharmaceutical companies.

In October, Baker filed a sweeping health care bill that would subject high-cost drugs to further state oversight and penalize companies that raise the price of any drug too sharply.

And in November, the Senate passed a bill that allows state officials to determine fair values for expensive medicines and to cap out-of-pocket costs for insulin.

House leaders are expected to introduce health care legislation in the new year.

Many organizations, including the consumer group Health Care For All, support stronger controls on prescription prices.

A coalition including Health Care For All, AARP Massachusetts, the Greater Boston Interfaith Organization, the Massachusetts Medical Society, and other groups told state officials this month that the proposed MassHealth regulations will save money for the state and taxpayers, while also protecting the 1.8 million residents who rely on the MassHealth program for their health care.

Some of the new MassHealth drug pricing provisions are already in effect. Since the law was enacted this summer, MassHealth officials said they already have negotiated discounts with five drug companies for 11 drugs, saving about $10 million.

Before discounts, the cost of drugs in MassHealth has grown to about $1.9 billion per year.

The administration and the Health Policy Commission plan to finalize their regulations over the next several weeks.

At a recent public hearing, Dr. John Christian Kryder, a board member of the Health Policy Commission, noted the difficult task for state officials.

The tradeoffs here are enormous if we dont get it right and create an environment where drug development does not occur, he said.

Priyanka Dayal McCluskey can be reached at priyanka. mccluskey@globe.com. Follow her on Twitter @priyanka_dayal.

Read the rest here:
Pharmaceutical industry mounts opposition to states effort to curb drug costs - The Boston Globe

Odonate Therapeutics Inc (ODT) is near the top in its industry group according to InvestorsObserver. ODT gets an overall rating of 46. That means it scores higher than 46 percent of stocks. Odonate Therapeutics Inc gets a 51 rank in the Biotechnology industry. Biotechnology is number 63 out of 148 industries.

Click Here to get the full Stock Score Report on Odonate Therapeutics Inc (ODT) Stock.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Odonate Therapeutics Inc (ODT) stock is down -3.69% while the S&P 500 has gained 0.03% as of 9:57 AM on Friday, Dec 27. ODT is down -$1.09 from the previous closing price of $29.53 on volume of 2,310 shares. Over the past year the S&P 500 is higher by 30.22% while ODT has gained 141.43%. ODT lost -$4.36 per share the over the last 12 months.

To see the top 5 stocks in Biotechnology click here.

More here:
Is Odonate Therapeutics Inc (ODT) a Winner or a Loser in the Biotechnology Industry - InvestorsObserver

It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an investment opportunity. As a result, most investors pick their illusory winners by making a superficial analysis and research that leads to poor performance on aggregate. Since stock returns aren't usually symmetrically distributed and index returns are more affected by a few outlier stocks (i.e. the FAANG stocks dominating and driving S&P 500 Index's returns in recent years), more than 50% of the constituents of the Standard and Poors 500 Index underperform the benchmark. Hence, if you randomly pick a stock, there is more than 50% chance that you'd fail to beat the market. At the same time, the 20 most favored S&P 500 stocks by the hedge funds monitored by Insider Monkey generated an outperformance of more than 8 percentage points so far in 2019. Of course, hedge funds do make wrong bets on some occasions and these get disproportionately publicized on financial media, but piggybacking their moves can beat the broader market on average. That's why we are going to go over recent hedge fund activity in Unity Biotechnology, Inc. (NASDAQ:UBX).

Unity Biotechnology, Inc. (NASDAQ:UBX) was in 4 hedge funds' portfolios at the end of September. UBX shareholders have witnessed a decrease in hedge fund interest recently. There were 5 hedge funds in our database with UBX positions at the end of the previous quarter. Our calculations also showed that UBX isn't among the 30 most popular stocks among hedge funds (click for Q3 rankings and see the video below for Q2 rankings). Video: Click the image to watch our video about the top 5 most popular hedge fund stocks.

5 Most Popular Stocks Among Hedge Funds

Why do we pay any attention at all to hedge fund sentiment? Our research has shown that hedge funds' large-cap stock picks indeed failed to beat the market between 1999 and 2016. However, we were able to identify in advance a select group of hedge fund holdings that outperformed the Russell 2000 ETFs by 40 percentage points since May 2014 (see the details here). We were also able to identify in advance a select group of hedge fund holdings that'll significantly underperform the market. We have been tracking and sharing the list of these stocks since February 2017 and they lost 27.8% through November 21, 2019. That's why we believe hedge fund sentiment is an extremely useful indicator that investors should pay attention to.

We leave no stone unturned when looking for the next great investment idea. For example Discover is offering this insane cashback card, so we look into shorting the stock. One of the most bullish analysts in America just put his money where his mouth is. He says, "I'm investing more today than I did back in early 2009." So we check out his pitch. We read hedge fund investor letters and listen to stock pitches at hedge fund conferences. We even check out this option genius' weekly trade ideas. This December, we recommended Adams Energy as a one-way bet based on an under-the-radar fund manager's investor letter and the stock already gained 20 percent. Keeping this in mind let's take a gander at the latest hedge fund action surrounding Unity Biotechnology, Inc. (NASDAQ:UBX).

Story continues

At the end of the third quarter, a total of 4 of the hedge funds tracked by Insider Monkey were bullish on this stock, a change of -20% from the previous quarter. The graph below displays the number of hedge funds with bullish position in UBX over the last 17 quarters. With hedge funds' positions undergoing their usual ebb and flow, there exists a few noteworthy hedge fund managers who were increasing their holdings considerably (or already accumulated large positions).

Is UBX A Good Stock To Buy?

Of the funds tracked by Insider Monkey, Citadel Investment Group, managed by Ken Griffin, holds the biggest position in Unity Biotechnology, Inc. (NASDAQ:UBX). Citadel Investment Group has a $2.3 million position in the stock, comprising less than 0.1%% of its 13F portfolio. Coming in second is Millennium Management, managed by Israel Englander, which holds a $1.3 million position; less than 0.1%% of its 13F portfolio is allocated to the stock. Other peers that are bullish consist of Oleg Nodelman's EcoR1 Capital, Paul Marshall and Ian Wace's Marshall Wace and . In terms of the portfolio weights assigned to each position EcoR1 Capital allocated the biggest weight to Unity Biotechnology, Inc. (NASDAQ:UBX), around 0.04% of its 13F portfolio. Millennium Management is also relatively very bullish on the stock, dishing out 0.0021 percent of its 13F equity portfolio to UBX.

Seeing as Unity Biotechnology, Inc. (NASDAQ:UBX) has witnessed declining sentiment from the smart money, it's safe to say that there exists a select few money managers who sold off their full holdings in the third quarter. It's worth mentioning that Michael Castor's Sio Capital dumped the largest position of the "upper crust" of funds monitored by Insider Monkey, valued at close to $1 million in stock. Mike Vranos's fund, Ellington, also dropped its stock, about $0.1 million worth. These transactions are intriguing to say the least, as total hedge fund interest was cut by 1 funds in the third quarter.

Let's now review hedge fund activity in other stocks - not necessarily in the same industry as Unity Biotechnology, Inc. (NASDAQ:UBX) but similarly valued. These stocks are Compugen Ltd. (NASDAQ:CGEN), ShotSpotter, Inc. (NASDAQ:SSTI), Tsakos Energy Navigation Ltd. (NYSE:TNP), and ADMA Biologics Inc (NASDAQ:ADMA). This group of stocks' market values resemble UBX's market value.

[table] Ticker, No of HFs with positions, Total Value of HF Positions (x1000), Change in HF Position CGEN,4,7644,-1 SSTI,6,12594,0 TNP,7,27496,1 ADMA,11,105915,1 Average,7,38412,0.25 [/table]

View table hereif you experience formatting issues.

As you can see these stocks had an average of 7 hedge funds with bullish positions and the average amount invested in these stocks was $38 million. That figure was $4 million in UBX's case. ADMA Biologics Inc (NASDAQ:ADMA) is the most popular stock in this table. On the other hand Compugen Ltd. (NASDAQ:CGEN) is the least popular one with only 4 bullish hedge fund positions. Compared to these stocks Unity Biotechnology, Inc. (NASDAQ:UBX) is even less popular than CGEN. Hedge funds clearly dropped the ball on UBX as the stock delivered strong returns, though hedge funds' consensus picks still generated respectable returns. Our calculations showed that top 20 most popular stocks among hedge funds returned 37.4% in 2019 through the end of November and outperformed the S&P 500 ETF (SPY) by 9.9 percentage points. A small number of hedge funds were also right about betting on UBX as the stock returned 26.6% during the fourth quarter (through the end of November) and outperformed the market by an even larger margin.

Disclosure: None. This article was originally published at Insider Monkey.

Related Content

See the rest here:
Here is What Hedge Funds Think About Unity Biotechnology, Inc. (NUBX) - Yahoo Finance

ROCKFORD, Ill. (WIFR) ----- Celebrating success as the University of Illinois College of Medicine Rockford honors its students at the Master of Science in Medical Biotechnology graduation on Saturday.

Twenty-six students received their degrees in a subject that focuses on the research and development of medical therapies, ranging from drugs and vaccines to diagnostic tests and medical devices.

As they prepare to enter the workforce, those with the school say these hardworking grads are set up for success.

"As the reputation of the program has expanded and individuals have been getting jobs all over the country and all over the world, we're getting more and more students," said Dean Alex Stagnaro-Green.

"My expectations are to essentially just further give back to the community and continue the work I've done here and the work I'm going to do in the future," said graduate Adijan Kuckovic.

Read the rest here:
Medical Biotechnology master's students celebrate their graduation at the University of Illinois College of Medicine Rockford - WIFR

CEO Vered Caplan says the move would enable the development and delivery of cell and gene therapies onsite at HYGEIA's hospitals in Greece

Inc (), a developer of advanced cell therapies, revealed Friday that it struck a strategic partnership agreement between the Theracell joint venture and the large HYGEIA Group which runs three hospitals in Greece.

In a statement, the Germantown, Maryland-based company said that under the terms of the agreement, the joint venture will implement point-of-care cell therapy platform for clinical development and commercialization of cell and gene therapies within the HYGEIA Groups network of hospitals in Greece.

and TheraCell Advanced Biotechnology earlier formed a joint venture to advance point-of-care platform in Greece, the Balkan region and some Middle Eastern countries.

The point-of-care platform is designed to collect, process and supply cells within the patient care setting for various treatments.

The main goal is to reduce the cost and complexity of supplying cell and gene therapies, said , as well as boostquality by integrating automated processing units and proprietary technologies.

Significantly, HYGEIA is the first hospital network in the region to implement Orgenesis point-of-care cell therapy platform. The partnership aims to provide the HYGEIA Group with resources to advance clinical development and deliver personalized, advanced therapies across its network for a range of diseases in oncology, hematology, orthopedics, nephrology, dermatology and diabetes.

This partnership with the HYGEIA Group further validates the significant value proposition of our point-of-care platform, as it enables the development and delivery of cell and gene therapies onsite at hospitals, said Orgenesis CEO Vered Caplan.

We believe this platform has the potential to transform the cell and gene therapy market, by bringing life-saving therapies to market in a much more time and cost-effective manner, she added.

The Orgenesis boss said Theracell had proved to be an ideal partner with extensive experience and capabilities in autologous cell therapy and regenerative medicine, and strong operations in Greece and relationships in the region.

We are in active discussions to establish PoCare locations and partnerships with hospitals and healthcare networks in other countries and regions across the world, said Caplan.

Greeces HYGEIA Group operates three hospitals with a capacity of 1,261 beds, 52 operating rooms, 19 delivery rooms and 10 intensive care units.

HYGEIA Group CEO Andreas Kartapanis said thanks to the partnership with Theracell and Orgenesis it would be the first hospital network in Greece to provide advanced cell and gene therapies.

We believe this partnership will provide us a strong competitive advantage in this rapidly developing field. More importantly, this partnership will benefit patients that will now have greater access to these important therapies, said Kartapanis.

For the fiscal third quarter ended September 30, Orgenesis generated meaningful revenue, over $1 million, through its rapidly advancing point-of-care cellular therapy platform.

Meanwhile, TheraCell has experience in the isolation, processing and application of adipose-derived stem cells, as well as somatic cells. It has developed a patented platform for tissue engineering and cell therapies in the areas of dermatology, articular cartilage defects, and chronic kidney injury.

Contact Uttara Choudhury at[emailprotected]

Follow her onTwitter:@UttaraProactive

Follow this link:
Orgenesis and Theracell to launch point-of-care cell and gene therapy centers in HYGEIA Group"s hospitals - Proactive Investors USA & Canada

Brokerages predict that Vir Biotechnology (NYSE:VIR) will report ($0.47) earnings per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Vir Biotechnologys earnings. The firm is scheduled to announce its next earnings report on Tuesday, February 18th.

On average, analysts expect that Vir Biotechnology will report full-year earnings of ($1.81) per share for the current financial year. For the next year, analysts forecast that the company will post earnings of ($1.97) per share, with EPS estimates ranging from ($2.05) to ($1.93). Zacks EPS calculations are a mean average based on a survey of sell-side analysts that follow Vir Biotechnology.

Vir Biotechnology (NYSE:VIR) last announced its quarterly earnings results on Tuesday, November 19th. The company reported ($4.60) earnings per share (EPS) for the quarter, missing the Thomson Reuters consensus estimate of ($3.71) by ($0.89). The business had revenue of $1.40 million for the quarter.

VIR has been the topic of several analyst reports. Barclays initiated coverage on Vir Biotechnology in a report on Tuesday, November 5th. They issued an overweight rating and a $25.00 target price on the stock. Cowen started coverage on shares of Vir Biotechnology in a research report on Tuesday, November 19th. They issued a buy rating on the stock. JPMorgan Chase & Co. started coverage on shares of Vir Biotechnology in a research note on Tuesday, November 5th. They issued an overweight rating and a $25.00 price objective on the stock. Goldman Sachs Group started coverage on shares of Vir Biotechnology in a research note on Tuesday, November 5th. They issued a buy rating and a $37.00 price objective on the stock. Finally, Robert W. Baird initiated coverage on shares of Vir Biotechnology in a research report on Wednesday, November 13th. They set a neutral rating for the company. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Vir Biotechnology currently has a consensus rating of Buy and an average target price of $29.00.

Shares of NYSE VIR traded down $0.40 during trading on Tuesday, reaching $12.62. The company had a trading volume of 178,796 shares, compared to its average volume of 158,772. The company has a fifty day simple moving average of $13.53. Vir Biotechnology has a 12 month low of $11.65 and a 12 month high of $16.50.

In related news, major shareholder Endurance (Cayman) Ltd Svf acquired 950,000 shares of the stock in a transaction dated Wednesday, October 16th. The stock was bought at an average price of $14.22 per share, for a total transaction of $13,509,000.00. Also, insider Abu Dhabi Investment Authority bought 1,000,000 shares of the companys stock in a transaction that occurred on Wednesday, October 16th. The shares were bought at an average price of $14.41 per share, for a total transaction of $14,410,000.00.

About Vir Biotechnology

Vir Biotechnology, Inc, a clinical-stage immunology company, develops therapeutic products for the treatment and prevention of serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus, and VIR-2020 for the prevention of tuberculosis.

See Also: Strike Price

Get a free copy of the Zacks research report on Vir Biotechnology (VIR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.

Read this article:
-$0.47 Earnings Per Share Expected for Vir Biotechnology (NYSE:VIR) This Quarter - Riverton Roll

PRINCETON, N.J., Dec. 03, 2019 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical stage immuno-oncology company with a broad pipeline of novel products based on the companys proprietary Versamune T-cell activating technology, today announced that Dr. Frank Bedu-Addo, President and Chief Executive Officer, is scheduled to present the company's upcoming clinical trials and recent clinical data demonstrating the potential of the Versamune-based products to overcome key limitations of current cancer immunotherapy at the 12th Annual LD Micro Main Event being held on December 10-12, 2019 at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.

Event: 12th Annual LD Micro Main EventFormat: Presentation & 1x1 MeetingsDate: Wednesday, December 11, 2019Time: 1:40pm PTLocation: Luxe Sunset Boulevard Hotel, Los Angeles, CA: Track 3

About PDS Biotechnology

PDS Biotechnology is a clinical-stage immuno-oncology company with a broad pipeline of novel products based on the companys proprietary Versamune T-cell activating technology. The Versamune platform effectively delivers tumor-specific antigens for in-vivo uptake and processing, while also activating a critical immunological pathway, the type 1 interferon pathway, thus resulting in the production of potent tumor-specific killer T-cells. Using Versamune, PDS Biotechnology is engineering therapies designed to better recognize cancer cells and break down their defense systems to effectively attack and destroy tumors. PDS Biotechnologys pipeline combines the Versamune technology with tumor-specific antigens across several cancer types. To learn more, please visit http://www.pdsbiotech.com or follow us on Twitter @pdsbiotech.

Forward Looking StatementsThis communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the Company) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Companys management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as may, will, should, would, expect, anticipate, plan, likely,believe,estimate,project,intend,and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the ability of the Company to integrate Edge and PDS Biotechnology following the merger; the Companys ability to protect its intellectual property rights; competitive responses to the completion of the merger; potential adverse reactions or changes to business relationships resulting from the completion of the merger;the Companys anticipated capital requirements, including the Companys anticipated cash runway and the Companys current expectations regarding its plans for future equity financings; the timing for the Company or its partners to initiate the planned clinical trials for its lead assets, PDS0101 and PDS0102; the Companys interpretation of the results of its Phase 1 trial for PDS0101 and whether such results are sufficient to support additional trials or the future success of such trials;the successful implementation of the Companys research and development programs and collaborations, including any collaboration studies concerning PDS0101 and the Companys interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Companys product candidates; the acceptance by the market of the Companys product candidates, if approved;the timing of and the Companys ability to obtain and maintainU.S. Food and Drug Administrationor other regulatory authority approval of, or other action with respect to, the Companys product candidates;and other factors, including legislative, regulatory, political and economic developmentsnot within the Companys control. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Companys annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Media & Investor Relations Contacts:

Tram Bui / Alexander LoboThe Ruth GroupPhone: +1-646-536-7035 / +1-646-536-7037Email: tbui@theruthgroup.com / alobo@theruthgroup.com

Continue reading here:
PDS Biotechnology to Present at the 12th Annual LD Micro Main Event - BioSpace

The All India Institute of Medical Sciences (AIIMS) has released the details of the entrance exam through which candidates will be shortlisted for admission into BSc and MSc courses. According to the details, AIIMS BSc Nursing, BSc Nursing (Post-Basic) and BSc (paramedical courses) admission entrance exam are scheduled for June 6, 20 and 28.

The exam for the admission to MSc Nursing, MSc Biotechnology and other MSc courses will be held on June 6 and July 4. The registration window for the MSc course will open on December 13 and for the BSc courses on December 12.

Candidates who have passed class 12th exams are eligible for the BSc programs and graduates are eligible for the MSc programs.

For the BSc nursing post-basic course candidates with Diploma in General Nursing and Midwifery from any institution recognized by the Indian Nursing Council and Registration as a nurse, RN, RM (registered nurse, registered midwife) with any State Nursing Council along with 10+2 qualification are eligible to apply.

The registration for both the courses will close on January 16, 2020.

Tags: Aiims Aiims Nursing Exam Aiims Biotechnology Exam Aiims Paramedical Admission Aiims Bsc Nursing Bsc Paramedical Courses

Read this article:
Admission details available for the AIIMS Nursing, Biotechnology and Paramedical admissions - Brainbuxa

Since PDS Biotechnology Corporation (NASDAQ:PDSB) and Axsome Therapeutics Inc. (NASDAQ:AXSM) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation of both companies.

Earnings & Valuation

Demonstrates PDS Biotechnology Corporation and Axsome Therapeutics Inc. earnings per share, gross revenue and valuation.

Profitability

Table 2 demonstrates the return on equity, net margins and return on assets of PDS Biotechnology Corporation and Axsome Therapeutics Inc.

Risk & Volatility

PDS Biotechnology Corporation has a 2.42 beta, while its volatility is 142.00% which is more volatile than Standard and Poors 500. From a competition point of view, Axsome Therapeutics Inc. has a 2.65 beta which is 165.00% more volatile compared to Standard and Poors 500.

Liquidity

PDS Biotechnology Corporations Current Ratio is 5 while its Quick Ratio is 5. On the competitive side is, Axsome Therapeutics Inc. which has a 5.7 Current Ratio and a 5.7 Quick Ratio. Axsome Therapeutics Inc. is better positioned to pay off short and long-term obligations compared to PDS Biotechnology Corporation.

Analyst Ratings

The next table highlights the given recommendations and ratings for PDS Biotechnology Corporation and Axsome Therapeutics Inc.

The consensus target price of PDS Biotechnology Corporation is $8.5, with potential upside of 201.42%. Competitively Axsome Therapeutics Inc. has a consensus target price of $48, with potential upside of 5.66%. The information presented earlier suggests that PDS Biotechnology Corporation looks more robust than Axsome Therapeutics Inc. as far as analyst belief.

Insider & Institutional Ownership

Roughly 28.3% of PDS Biotechnology Corporation shares are owned by institutional investors while 46.3% of Axsome Therapeutics Inc. are owned by institutional investors. About 6.5% of PDS Biotechnology Corporations share are owned by insiders. Comparatively, Axsome Therapeutics Inc. has 2.2% of its share owned by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year PDS Biotechnology Corporation has weaker performance than Axsome Therapeutics Inc.

Summary

On 6 of the 11 factors Axsome Therapeutics Inc. beats PDS Biotechnology Corporation.

Axsome Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the management of central nervous system (CNS) disorders. The companys product candidates include AXS-05 that is in Phase III trial for the treatment of treatment resistant depression and Alzheimers disease agitation; and AXS-02, which is in Phase III trial to treat complex regional pain syndrome, knee osteoarthritis related to bone marrow lesions, and chronic low back pain related to Modic changes. It is also developing AXS-06, a preclinical product candidate for CNS disorders, including chronic pain. The company was founded in 2012 and is based in New York, New York.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Follow this link:
Comparison of PDS Biotechnology Corporation (PDSB) and Axsome Therapeutics Inc. (NASDAQ:AXSM) - The Broch Herald

Crystal market research acknowledges the inclusion of a second report to a Global Biotechnology Market. The report summarizes the players that are perceptible in the Biotechnology market with an exact objective to provide a rationalist and purpose of their unpretentious forces of this current Biotechnology market, as the provincial and product segments are likewise expected at length, bearing in mind the Biotechnology objective to grant a granular example of this economys collapse.

The Biotechnology report expands coverage of business and market trends that are chief. The Biotechnology industry research incorporates require, predictions and classical market data, application information and cost trends, and business stocks. The Biotechnology analysis divides the sector dimensions, by price and volume, dependent on geography and application type.

Get the FREE PDF of this Research Report Now! @https://www.crystalmarketresearch.com/report-sample/HC012294

Continued

Inquiry More about this Research Report Now!: https://www.crystalmarketresearch.com/send-an-enquiry/HC012294

Check Exclusive Discount on this report @https://www.crystalmarketresearch.com/check-discount/HC012294

Contacts Us:

Sherry | APAC Marketing Division: Level 23-1, Premier Suite

Mont Kiara, 50480 Kuala Lumpur

Malaysia

E-mail: sales@crystalmarketresearch.com

Read more from the original source:
New innovative report on Biotechnology Market to Boom In Near Future by Industry Key Players: Merck & Co,Abbott Laboratories,Novo Nordisk - Day...

Shutterstock

China is rapidly gaining on the United States when it comes to creating technology that mitigates disease threats and developing pharmaceuticals faster, and its a phenomenon driven by a philosophy that the state, military, and the private sector are one in the same.

That was the testimony of Tara J. OToole, senior fellow and executive vice president at In-Q-Tel, before the U.S. Senate Armed Services Subcommittee on Emerging Threats and Capabilities. The hearing, Biological Threats to U.S. National Security, examined everything from Chinas push to develop biotechnology infrastructure to luring research scientists away from the United States to work in China.

China has said repeatedly and forcefully, and theyre backing up their words with actions, that they intend to own the biorevolution, OToole said. And they are building the infrastructure, the talent pipeline, the regulatory system, and the financial system they need to do that.

China is partly accomplishing this by combining its internet giants, such as Alibaba, with its biotech companies. The combined strength of these companies research focuses on the industrialization of artificial intelligence in which China is institutionalizing it whereas the United States is only experimenting with it, OToole added.

Chinas goal is to make biotechnology 5 percent of the countrys GDP by 2020. China has changed regulations for its own version of the Food and Drug Administration to be more like that of the United States in order to more easily market to the world. The country has created a talent pipeline that incentivizes its own students to go into the life sciences and bioengineering. China also has at least 20 programs intended to bring scientific talent from the rest of the world.

There are good reasons China is going after the biorevolution: it has the highest incidences of cancer on earth and the population is aging. It also must find an affordable way to deliver health care to a rising middle class.

And China is delivering health care to the world. The country is the largest producer of active pharmaceutical ingredients. However, reliance on foreign pharmaceuticals has national security implications. As many as 80 to 100 percent of critical drugs are manufactured outside the United States. U.S Sen. Gary Peters (D-MI) told the committee that following the 2001 anthrax attacks, the U.S. was dependent on a single foreign source for a broad-spectrum antibiotic to treat anthrax.

To what extent is the U.S. reliant on foreign sources for key drug products and medical supplies such as syringes and needles and other critical medical supplies that we would need to respond to a biological attack today? Peters asked the panel of experts.

The United States is critically dependent on China for several drugs and has been shipping manufacturing capacity to Asia for more than a decade.

There isnt a CEO of a major pharma company that hasnt been recruited by China to build facilities there, OToole said.

To address the drug supply chain, the United States has begun exploring the possibility of using synthetic biology to make active pharmaceutical ingredients, especially in response to epidemics.

If there were a natural pandemic in which the entire world needed drugs, Im sure China, as we would, take care of its own people first. Yet, we dont have the surge capacity to produce enough very common, well-used medicine in time to deal with an epidemic, OToole said.

Thomas Inglesby, director of the Center for Health Security at the Johns Hopkins Bloomberg School of Public Health, told the committee that the U.S. treats medicines too much like commodities that can be sourced for the lowest price somewhere in the world.

In a crisis, everyone in every part of the world would be looking for medicine at the same time, Inglesby said. There should be at least a strategic examination of the kinds of things we must have, and we should consider how to bring some of those medicines back to the U.S. Obviously that cant be done with all medicines. Were an interconnected world. But for national health crises, we should be thinking about making them here.

Part of the problem is that the United States has not done a good job at translating biology to products, OToole said, or building infrastructure for securing and promoting the bioeconomy. Our translational infrastructure for biology is mostly coming from small start-up companies in the private sector, which are the innovation engines for biology, but do not provide the robust infrastructure to manage epidemics, whether deliberate or natural.

The experts made the following recommendations:

* Take on synthetic biology as a national security priority;* Use the National Defense Education Act to improve access to stem education and establish greater scientific careers within the U.S. government;* The contingency fund levels for the Centers for Disease Control and Prevention and USAID should be increased and sustained;* Support and strengthen the militarys infectious disease research laboratories;* Provide strong, coherent leadership at the National Security Council essential for guaranteeing effective oversight, long before a crisis emerges;* The U.S. Department of Agriculture should prioritize stronger crop surveillance, animal wildlife surveillance, more support for animal vaccine development, and more funding for agricultural biodefense overall;* Strongly support the biological weapons convention.

During epidemics, the U.S. should be able to immediately create diagnostics that could be used similarly to a pregnancy test so that people can determine for themselves who is sick and who isnt. Officials should be able to rapidly develop a new vaccine in response to an epidemic, OToole added.

These same tools also apply to diseases that affect agriculture and the U.S. animal supply. More than half of all infections that people contract are spread by animals.

Ill start by acknowledging that mother nature is a really good terrorist, Julie L. Gerberding, co-chair of the Commission on Strengthening Americas Health Security at the Center for Strategic and International Studies, told the committee. China today is experiencing a dreadful outbreak of swine fever that has probably cost the death or culling of at least 50 percent of their entire population of pork which is a major source of protein for people in China. So, this is a major socioeconomic threat to the state of China today and thats mother nature.

Swine fever, however, is not spread to humans, though it has a devastating economic impact. And U.S. farmers are concerned about trade and travel bringing such infectious diseases to this country.

I would say that the first alarming statistic is that we spend probably about 100 times less on agricultural threats than we do on human threats, Inglesby said. I think there are many reasons for this. But one includes a kind of reluctance within the U.S. government to talk about this threat until quite recently.

Continue reading here:
Chinese biotechnology dominates US Senate hearing on biological threats - Homeland Preparedness News

On the second floor of the Pennovation Center, Strella Biotechnology is hard at work turning their student-led startup into a full-fledged company thats ready to make a major impact in the agricultural sector.

May graduates Katherine Sizov and Malika Shukurova, respectively the CEO and head of R&D at Strella, share a 2019 Presidents Innovation Prize, which includes $100,000 of financial support, a $50,000 living stipend for both awardees, and a year of dedicated co-working and lab space at the Pennovation Center. The alumnae and their company are now poised to take on the challenge of $1 trillion worth of food waste.

Strellas biosensors are designed to give packers real-time data on how ripe their fruits are while being stored between harvesting and selling. Using bio-inspired sensors that measure the ethylene gas produced by fruits as they ripen, Strella successfully hacked the fruit to create their patent-pending biosensors. Now, only six months after graduation, Strella has six paying customers and is aiming for $100,000 in sales by the end of the season.

Beyond the work needed to deploy their first paid product, Strella also has a clear view of what needs to be done for future progress of the company. This means running experiments in the lab to refine their current sensors while conducting other experiments that will help the company be able to monitor other types of fresh foods. Its a job that Shukurova says involves a lot of multitasking and requires an all-hands approach to problem solving.

We set up experiments that run for several days, and during that period we work on different tasks. I prepare for the next set of experiments, Jacob [Jordan] and Katherine travel to our customers to deploy sensors, and Zuyang [Liu]]works on IoT [Internet of Things]. At the end of the day we all come together to discuss results and future plans, says Shukurova about their companys work flow.

The company is also finding ways to expand their technology onto individual pallets in retail settings, which represents a huge untapped market for managing food waste. That opportunity, from a numbers perspective, is far greater than the current packing market were working in, so were hoping to make an impact as we move into that space as well, says Sizov.

During the next six months, the team will be busy analyzing the data collected by their deployed sensors and gearing up for a new round of fundraising. Looking further ahead, Strella aims to increase sales in their initial market, conduct research and development on individual pallet-level sensors, and begin active partnerships with larger retailers to help optimize their supply chains.

Sizov admits that Strella has an ambitious timeline but that the team is looking forward to the challenge. Working alongside Jordan, Liu, and Shukurova, Sizov says that Strella already has its own culture of sorts. None of us have ever had a business before, and learning how to create culture within a group, how to work together as a team, and how to not get tired of each other because we spend so much time together, has been an interesting challenge, says Sizov.

Their lab and coworking space at Pennovation has allowed Strella to stay connected with Penns innovator community while also providing lab facilities and resources needed to continue their work on their sensors. Strella has two lab benches and a fume hood, access to shared lab equipment, and plenty of space to house their prototypes, all provided for free as part of their Innovation Prize.

Theyve also been able to stay well-connected to the Penn community as a whole, traveling regularly to campus to meet with faculty, including weekly meetings with their mentorJeffrey Babin. We are not out of [the] Penn mindset, says Shukurova. We dont have to worry about exams, but were still on campus and were still involved with the faculty.

Babin says that Strella is one of the most exciting companies that Ive seen come out of Penn and that the company is in a strong position to make some significant impact on the food supply chain. One of the things thats been strong since the beginning was having an expanded vision: Not just on product development, but getting a customer, he says. They have a really strong sense of whats required to acquire a customer, what the next steps are, and growing both within the initial customer base while expanding to other elements.

When asked what advice they would give to would-be entrepreneurs, Shukurovas advice is to take it as a journey. She encourages students who have an idea to share their thoughts with others to get feedback before beginning any startup endeavor. Talk to more peopledont limit yourself to 10 people, or 20 people, talk to hundreds of people, she says.

Sizov says that the experience of running a startup has been a great learning experience, one that is far less risky than might seem at first, especially thanks to the Innovation Prize. If youre just following your passion, thats not a risk. Youre not putting aside your career, she says. Everything we learn at Strella is directly teaching us how to be better and smarter individuals.

Jeffrey Babin is a practice professor and associate director of the Engineering Entrepreneurship Program in the School of Engineering and Applied Science.

Homepage photo: Presidents Innovation Prize winners Katherine Sizov and Malika Shukurova (front) doing R & D to help design new versions of their fruit-hackingbiosensors at the Pennovation center.

Original post:
Strella Biotechnology tackles food waste by 'hacking the fruit' - Penn: Office of University Communications

Aravive Inc (ARAV) is near the top in its industry group according to InvestorsObserver. ARAV gets an overall rating of 81. That means it scores higher than 81 percent of stocks. Aravive Inc gets a 98 rank in the Biotechnology industry. Biotechnology is number 87 out of 148 industries.

Click Here to get the full Stock Score Report on Aravive Inc (ARAV) Stock.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 81 means the stock is more attractive than 81 percent of stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Aravive Inc (ARAV) stock has fallen -15.53% while the S&P 500 has gained 0.17% as of 10:44 AM on Wednesday, Nov 27. ARAV is lower by -$1.46 from the previous closing price of $9.40 on volume of 1,348,672 shares. Over the past year the S&P 500 has risen 17.28% while ARAV has gained 43.06%. ARAV lost -$6.00 per share the over the last 12 months.

To screen for more stocks like ARAV click here.

View post:
Where Does ARAV Stock Rank in the Biotechnology Industry? - InvestorsObserver

Robert W. Baird began coverage on shares of Vir Biotechnology (NYSE:VIR) in a report released on Wednesday, November 13th, The Fly reports. The firm issued a neutral rating on the stock.

Other analysts have also issued reports about the company. Cowen assumed coverage on Vir Biotechnology in a report on Tuesday, November 5th. They set an outperform rating on the stock. Goldman Sachs Group began coverage on Vir Biotechnology in a research note on Tuesday, November 5th. They issued a buy rating and a $37.00 price objective on the stock. Barclays began coverage on Vir Biotechnology in a research note on Tuesday, November 5th. They issued an overweight rating and a $25.00 price objective on the stock. Finally, JPMorgan Chase & Co. began coverage on Vir Biotechnology in a research note on Tuesday, November 5th. They issued an overweight rating and a $25.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Vir Biotechnology currently has an average rating of Buy and an average target price of $29.00.

VIR stock traded up $0.07 during trading hours on Wednesday, hitting $11.90. 101,085 shares of the stock were exchanged, compared to its average volume of 164,664. Vir Biotechnology has a 12 month low of $11.65 and a 12 month high of $16.50.

Vir Biotechnology (NYSE:VIR) last posted its quarterly earnings data on Tuesday, November 19th. The company reported ($4.60) earnings per share for the quarter, missing the consensus estimate of ($3.71) by ($0.89). The business had revenue of $1.40 million during the quarter.

In other Vir Biotechnology news, major shareholder Endurance (Cayman) Ltd Svf bought 950,000 shares of the companys stock in a transaction on Wednesday, October 16th. The stock was acquired at an average price of $14.22 per share, for a total transaction of $13,509,000.00. Also, insider Abu Dhabi Investment Authority bought 1,000,000 shares of the companys stock in a transaction on Wednesday, October 16th. The shares were acquired at an average price of $14.41 per share, with a total value of $14,410,000.00.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, a clinical-stage immunology company, develops therapeutic products for the treatment and prevention of serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus, and VIR-2020 for the prevention of tuberculosis.

Further Reading: What are the qualifications of a portfolio manager?

Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.

See the original post:
Vir Biotechnology (NYSE:VIR) Coverage Initiated by Analysts at Robert W. Baird - TechNewsObserver

I had one of those way-cool moments and what I now call the most memorable experience of my life this past week in Mombasa, Kenya.

It all started in late October, when I received an invitation from the African Agricultural Technology Foundation (AATF) to attend the Open Forum on Agricultural Biotechnology in Africa (OFAB) 2019 Media Awards on Nov. 21.

The AATF is a nonprofit organization focused on providing smallholder farmers in sub-Saharan Africa with practical technology solutions capable of addressing their farm productivity constraints and improving their livelihoods. One of its initiatives is OFAB, which works to enhance knowledge-sharing and awareness on agricultural biotechnology across seven African countries: Kenya, Tanzania, Ghana, Ethiopia, Uganda, Nigeria and Burkina Faso.

Exactly 18 days after receiving AATFs invitation, OFAB-Nigeria named me best agricultural biotechnology reporter in the print and online category and overall journalist of the year for my entry GMO debate affects public sentiment in Nigeria. I understood then that AATFs email was but a confirmation that I would be representing Nigeria at the continental level of the media awards in Mombasa.

As is typical of Mombasas fluctuating tropical climate, it was a relatively cool evening when the crme de la crmeof Africas science journalists joined scientists and policymakers from the seven OFAB countries for the media awards ceremony at the Sarova Whitesands Hotel. Dressed in a light-blue striped, knee-level kaftan, a black cap and a green-white-green traditional scarf, I joined the throng of people dressed primarily in their own colorful national and traditional garb.

Eugenia Abu, a veteran multimedia journalist who spoke on behalf of the panel of judges, said the awards were intended to acknowledge excellence in science journalism. We congratulate all the winners and urge for more synergy between science and journalism to enable AATF and OFAB to promote better lives for small-holder farmers on the continent through technology, Abu said.

As the crowd cheered, I heard my name announced as the winner in the print and online category. Visibly excited, but also bewildered, I began making my way to the stage. Many thoughts raced through my head at that auspicious moment, such as why are farmers in Africa slow in adopting agricultural innovations? I recalled that in developing my award-winning piece, I had interviewed many people on the streets who did not know what genetically modified organisms (GMOs) are or understand the term biotechnology.

Moreover, I thought again, studies have shown that our current trajectory for crop yields is insufficient to nourish the worlds population by 2050. Hence, with the worlds growing population and climate change, theres a need for greater and more consistent food production around the globe. This is particularly true in Africa, which is projected to hit 2.2. billion people by 2050.

Africa cannot achieve food sufficiency or realize its dream of becoming the food basket of the world without farmers having access to improved seeds, agricultural tools and technology on their farms. Thus journalists have a critical role to play in informing and educating African farmers and consumers about advances in modern agriculture and ensuring that farmers have access to options, including biotechnology. My aim is to connect these scientific innovations and technology to farmers in Africa through better communication.

On Nov. 23, as my Ethiopian Airlines return flight touched down in Abuja, I was filled with a sense of satisfaction for all that had transpired in Mombasa as well as nostalgia for the incredibly talented African journalists with whom I had shared the homey hospitality of the Sarova Whitesands Hotel for the past three days.

As a science journalist, I also felt a strong reconfirmation of my belief that Africas agriculture needs science and technology more than any other continent in the world. Consequently, African journalists must understand and believe in the potential of science and technology so as to report, write and communicate science accurately and spur economic development on the continent.

Asante!

Abdullahi Tsanni is a Nigerian science writer and Alliance for Science contributor.

Read the rest here:
Using media to connect African farmers with scientific innovation and technology - Alliance for Science

Global Biotechnology Marketis expected to grow at a CAGR of 14% to reach US$ 1,254.1 million in 2024. The growth is coupled with rising demand of modern and innovative technologies such as DNA sequencing, recombinant technology, fermentation, tissue engineering. Further, rising demand for food to meet the need of ever increasing population and scarce availability of non-renewable natural resources also expected to drive the biotechnology market. Application of Genetic engineering and Genetic Modification (GM) processes to agricultural food products also expected to drive the business growth. Furthermore, decreasing prices of DNA sequencing technologies will encourage R&D activities to better understand genetic variations and develop therapeutic solutions.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/10844

Moreover, development of novel techniques and their implementation by the organisation by collaborating with the other participants will drive the Global Biotechnology Market. Further, increasing demand for therapeutic and diagnostic solutions on principles of red biotechnology, DNA sequencing, and recombinant technology is expected to drive the Global Biotechnology Market through 2024. Increasing prevalence of diseases such as hepatitis B, cancer, and other orphan disorders is also expected to fuel demand in the forecast period.

In 2017, North America dominated the overall market. The market growth is driven by the increasing R&D investments relating to new drug discovery and development. U.S. held highest market in North America due to increasing level of per capita spending on healthcare than other countries and has a high growth rate amongst other countries. According to the estimates published by OECD Health Statistics in 2014, it has been estimated that in 2012, U.S. spent nearly 16.9% of its GDP towards healthcare expenditure, which is the highest. The fact supports the estimated share of Global Biotechnology Market.

Asia Pacific is expected to have higher growth rate in the forecast period owing to the presence of patient awareness, rapidly improving healthcare infrastructure, and rising healthcare expenditure levels in the emerging markets. Global Biotechnology Market include the developing economies of China and India.

In 2017, nanobiotechnology held the highest market share. The Global Biotechnology Market growth is driven by fermentation and cell-based assay segments owing to rising R&D initiatives by various biotechnological and pharmaceutical companies.

DO INQUIRY BEFORE PURCHASING REPORT HERE:https://www.maximizemarketresearch.com/inquiry-before-buying/10844

Global Biotechnology Market

Market Segmentation By Technologyo DNA Sequencingo Nanobiotechnologyo Tissue engineering and Regenerationo Fermentationo Cell Based Assayo PCR Technologyo Chromatography Marketo Others

By Applicationso Healtho Food & Agricultureo Natural Resources & Environmento Industrial Processingo Bioinformaticso Others

The above data will be provided for following regions/countries from 2013-2024 (USD Million)

North Americao U.S.o Canada

Europeo Germanyo UKo Franceo Spaino Italy

Asia Pacifico Chinao Indiao Japano Australia

Latin Americao Argentinao Brazilo Mexico

Middle East and Africao South Africao Saudi Arabia

MAJOR TOC OF THE REPORT

Chapter One: Biotechnology Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Biotechnology Market Competition, by Players

Chapter Four: Global Biotechnology Market Size by Regions

Chapter Five: North America Biotechnology Revenue by Countries

Chapter Six: Europe Biotechnology Revenue by Countries

Chapter Seven: Asia-Pacific Biotechnology Revenue by Countries

Chapter Eight: South America Biotechnology Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Biotechnology by Countries

Chapter Ten: Global Biotechnology Market Segment by Type

Chapter Eleven: Global Biotechnology Market Segment by Application

Chapter Twelve: Global Biotechnology Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Biotechnology Market Report at:https://www.maximizemarketresearch.com/market-report/global-biotechnology-market/10844/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Lumawant Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website: http://www.maximizemarketresearch.com

Read more here:
Global Biotechnology Market : North America Is Expected To Account For Higher Market Share Of More Than 45% Driven By Increasing Investment In Us On...

PRINCETON, N.J., Nov. 25, 2019 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Companys proprietary Versamune T-cell activating technology, today announced that Lauren V. Wood, M.D., Chief Medical Officer of PDS Biotechnology, has been selected to deliver an oral presentation on the Companys novel T-cell activating immunotherapy platform, Versamune, at the World Vaccine & Immunotherapy Congress West Coast 2019, taking place on December 2-5, 2019 in San Francisco, CA.

Details for the presentation are below:

Presentation Title: Versamune: A Novel T-cell Activating Immunotherapy PlatformTopic: Engaging T-Cells, Cancer Antibodies, and CombinationsPresenter: Dr. Lauren V. Wood, Chief Medical Officer, PDS BiotechnologyDate: Wednesday, December 4, 2019Time: 3:00pm PST

The Versamune platform is PDS Biotechs proprietary, synthetic lipid-based T-cell activating platform, which works by facilitating several critical immunological pathways. Versamunes mechanism of action involves the effective cross-presentation of tumor antigens via the MHC Class I and Class II pathways to prime tumor-specific CD8+ and CD4+ T-cells as well the potent up-regulation of Type 1 interferon genes within the lymph nodes, promoting effective T-cell migration, activation and proliferation. These mechanisms promote strong in-vivo induction of polyfunctional tumor-targeting CD8+ killer T-cells. Versamunes activation specifically of type 1 interferons coupled with the lack of significant systemic cytokine release results in a highly favorable safety profile that has potential uses in combination with checkpoint inhibitors and other therapeutic agents. In a phase 1 human clinical trial PDS Biotechnologys lead Versamune-based immunotherapy exhibited potent antigen-specific CD8+ T-cell induction with an average of over 20-fold increase in the blood circulation within 14 days of treatment. The strong T-cell induction also resulted in complete regression of lesions in the majority of treated cervical intraepithelial neoplasia (CIN) patients. The ability to induce high levels of CD8+ killer T-cells in vivo has resulted in potent synergy with checkpoint inhibitors in preclinical studies. Upcoming phase 2 clinical trials to confirm the unique synergy will also be presented.

About PDS Biotechnology

PDS Biotechnology is a clinical-stage immuno-oncology company developing multiple therapies based on the Companys proprietary Versamune T-cell activating technology platform. The Versamune platform effectively delivers tumor-specific antigens for in-vivo uptake and processing, while also activating a critical immunological pathway, the type 1 interferon pathway, thus resulting in the production of potent tumor-specific killer T-cells. Using Versamune, PDS Biotechnology is engineering therapies designed to better recognize cancer cells and break down their defense systems to effectively attack and destroy tumors. PDS Biotechnologys pipeline combines the Versamune technology with tumor-specific antigens across several cancer types. To learn more, please visit http://www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

About PDS0101

PDS Biotechnologys lead candidate, PDS0101, combines the utility of the Versamune platform with targeted antigens in HPV-expressing cancers. In partnership with Merck and the National Cancer Institute (NCI), PDS Biotechnology is advancing PD0101 to Phase 2 studies in head and neck cancer and in HPV-related advanced cancer.

Forward Looking Statements

This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the Company) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Companys management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as may, will, should, would, expect, anticipate, plan, likely,believe,estimate,project,intend,and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the ability of the Company to integrate Edge and PDS Biotechnology following the merger; the Companys ability to protect its intellectual property rights; competitive responses to the completion of the merger; potential adverse reactions or changes to business relationships resulting from the completion of the merger;the Companys anticipated capital requirements, including the Companys anticipated cash runway and the Companys current expectations regarding its plans for future equity financings; the timing for the Company or its partners to initiate the planned clinical trials for its lead assets, PDS0101 and PDS0102; the Companys interpretation of the results of its Phase 1 trial for PDS0101 and whether such results are sufficient to support additional trials or the future success of such trials;the successful implementation of the Companys research and development programs and collaborations, including any collaboration studies concerning PDS0101 and the Companys interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Companys product candidates; the acceptance by the market of the Companys product candidates, if approved;the timing of and the Companys ability to obtain and maintainU.S. Food and Drug Administrationor other regulatory authority approval of, or other action with respect to, the Companys product candidates;and other factors, including legislative, regulatory, political and economic developmentsnot within the Companys control. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Companys annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Story continues

Read this article:
PDS Biotechnology to Present at the World Vaccine & Immunotherapy Congress West Coast 2019 - Yahoo Finance